Acerus Pharmaceuticals (OTCMKTS:ASPCF – Get Free Report) and Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.
Volatility & Risk
Acerus Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Hillstream Biopharma has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Valuation & Earnings
This table compares Acerus Pharmaceuticals and Hillstream Biopharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acerus Pharmaceuticals | $2.12 million | 0.80 | -$33.82 million | ($3.57) | -0.06 |
| Hillstream Biopharma | N/A | N/A | -$35.92 million | ($1.15) | -1.75 |
Acerus Pharmaceuticals has higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Acerus Pharmaceuticals and Hillstream Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acerus Pharmaceuticals | -924.33% | N/A | -74.62% |
| Hillstream Biopharma | N/A | -31.50% | -24.72% |
Insider & Institutional Ownership
1.2% of Hillstream Biopharma shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Acerus Pharmaceuticals and Hillstream Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acerus Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| Hillstream Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Summary
Hillstream Biopharma beats Acerus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.
About Hillstream Biopharma
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
